Carl Byrnes

Stock Analyst at Northland Securities

(0.30)
# 4,463
Out of 4,690 analysts
284
Total ratings
36.9%
Success rate
-3.4%
Average return

Stocks Rated by Carl Byrnes

Connect Biopharma Holdings
Apr 24, 2026
Maintained: Buy
Price Target: $7.5
Current: $2.23
Upside: +236.32%
MiMedx Group
Apr 17, 2026
Maintained: Buy
Price Target: $10$6
Current: $4.50
Upside: +33.33%
ARS Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $25
Current: $5.89
Upside: +324.45%
AVITA Medical
Mar 26, 2026
Maintained: Buy
Price Target: $10
Current: $10.35
Upside: -3.38%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $36.38
Upside: -6.54%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13$8
Current: $4.83
Upside: +65.63%
Spectral AI
Mar 19, 2026
Maintained: Buy
Price Target: $6
Current: $1.57
Upside: +282.17%
SANUWAVE Health
Mar 16, 2026
Maintained: Buy
Price Target: $55
Current: $4.68
Upside: +1,076.47%
Indivior Pharmaceuticals
Feb 27, 2026
Maintained: Buy
Price Target: $50
Current: $34.87
Upside: +43.39%
BrainsWay
Jan 22, 2026
Maintained: Buy
Price Target: $12$15
Current: $14.30
Upside: +4.90%
Maintained: Buy
Price Target: $10
Current: $4.95
Upside: +102.02%
Reiterated: Buy
Price Target: $9$4
Current: $0.3266
Upside: +1,124.74%
Maintained: Buy
Price Target: $5
Current: $0.6901
Upside: n/a
Rated: Hold
Price Target: $2$1.25
Current: $13.97
Upside: n/a
Initiated Coverage: Buy
Price Target: $8
Current: $1.84
Upside: n/a
Downgraded: Sell
Price Target: $8$1
Current: $0.0001
Upside: n/a
Maintained: Buy
Price Target: $10$2
Current: $0.0001
Upside: n/a
Maintained: Buy
Price Target: $4$2
Current: $32.36
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $2.25
Upside: n/a
Initiated Coverage: Buy
Price Target: $45
Current: $66.58
Upside: n/a
Initiated Coverage: Buy
Price Target: n/a
Current: $16.67
Upside: n/a